Rivastigmine

The Alzheimer’s disease therapeutics market is projected to grow from USD 5.5 billion in 2023 to USD 30.8 billion by 2033, at a CAGR of 18.8%, driven by an aging global population and advancements in treatment. North America leads with a 42.5% share in 2023. Key factors include increased awareness, a robust drug pipeline, and rising prevalence of Alzheimer’s disease worldwide.

A 10-year study by Karolinska Institutet found that cholinesterase inhibitors (ChEIs) like donepezil and galantamine showed promise in reducing cognitive decline in LBD, with rivastigmine reducing mortality risk. Higher ChEI doses provided greater cognitive benefits, but memantine showed no significant cognitive effect. The study highlights the need for long-term follow-ups and the lack of universal benchmarks for cognitive decline reduction.

The $500 million energy storage project by Jupiter Power, part of The Davis Cos.' Everett Docklands Innovation District, received state approval. The 700-megawatt project, set to begin in 2026 and complete in 2027, aims to support Massachusetts' climate goals by reducing fossil fuel dependence.

UChicago hosts Oct. 30 event featuring scholars and leaders discussing climate and energy policy, launching a new institute addressing climate change and sustainable growth. Panels focus on U.S. and global climate policy, energy storage, clean tech, and climate systems engineering. Event includes a climate showcase, student poster session, and career fair.

Constellation Energy plans to restart Three Mile Island's reactor under a 20-year deal with Microsoft for carbon-free energy supply to data centers. The move symbolizes a nuclear power revival, supported by financial institutions pledging increased investment. The restart aims to meet rising power demand from data centers and Microsoft's commitment to be carbon negative by 2030.